Case Study · Primary Biliary Cholangitis (Rare Disease)

A rare disease rescue.
21 hepatology sites, faster than expected.

How AcceleTrial helped a global biopharma company rapidly add specialist PBC sites to an ongoing study, clearing legal CDA cycles and compressed timelines through platform automation.

Resources/Case Studies/Primary Biliary Cholangitis Study
Therapeutic AreaPrimary Biliary Cholangitis
CustomerGlobal Biopharma
Platform UsedAcceleTrial®
Sites Target / Delivered20 needed / 21 provided

The Challenge

Rare disease. Rescue context.
Legal and clinical timelines running in parallel.

Adding sites to an ongoing rare disease study while navigating compressed timelines and legal CDA cycles required a platform capable of managing multiple parallel workflows without losing speed.

01
Identifying 20 additional sites in a rare disease indication

The sponsor needed 20 additional clinical sites for a Primary Biliary Cholangitis study. PBC is a rare disease with a limited pool of sites that have genuine hepatology expertise and the right patient population.

02
Compressed timelines with legal CDA overhead

Legal CDA negotiation had to run in parallel with clinical feasibility outreach and document collection, all within a compressed rescue timeline.

03
Efficient activation to meet rescue timelines

As a rescue engagement, urgency was elevated. Sites needed to be activated efficiently and quickly. Any delay in identification or document execution had immediate impact on the study's enrollment trajectory.

The Solution

21 hepatology sites.
2 to 3 days, plus internal CDA support.

Using AcceleTrial, LINEA System identified 21 sites with specific hepatology trial expertise and the right PBC patient access profile. Turnaround for feasibility and CDAs was 2 to 3 days, exceeding the sponsor's expectations.

LINEA incorporated its internal CDA negotiation service to handle the legal cycle in parallel with clinical qualification. All study documents were collected at 50% the standard timeline. Sites were evaluated across trial history, COVID-readiness, debarment status, and clinical experience.

Site Qualification and Service Criteria
Hepatology Trial ExperienceTrial HistoryCOVID-ReadinessDebarment CheckPatient AccessInternal CDA Negotiation
AcceleTrial® | PBC Rescue Study Performance
21
Sites IdentifiedHepatology specialist sites, exceeding target of 20
2-3
Days to Feasibility and CDAsIncluding internal CDA negotiation, turnaround exceeded expectations
18
Sites Approved for PSV18 of 21 LINEA sites received Protocol Site Visit approval
50%
Faster Document CollectionAll study documents at half the standard timeline

Outcomes

Rescue delivered.
Rare disease expertise at speed.

21
Sites Identified

21 hepatology specialist sites identified against a target of 20, each qualified against protocol criteria for this rare PBC indication.

18
Sites Approved for PSV

18 of LINEA's 21 sites received Protocol Site Visit approval, an 86% PSV approval rate from a rescue-context site pool.

2-3 Days
Feasibility Turnaround

Feasibility and CDAs completed in 2 to 3 days, including LINEA's internal CDA negotiation, exceeding sponsor expectations.

50%
Faster Document Collection

All necessary study documents collected at 50% the standard timeline, eliminating manual coordination delays.

Get the Full Story

Download the case study
or see AcceleTrial live

Get the one-page PDF summary or request a personalized demo using your protocol and therapeutic area.

We use cookies and analytics tools to understand how visitors use our site and to improve your experience. Learn more